Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)
Post# of 721
(Total Views: 118)
Posted On: 09/29/2017 5:17:55 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Tech Discussed at “Cannabis in the Capital Markets” Event
- Clinical studies of TurboCBD™ a topic of discussion at Canadian Securities Exchange-sponsored “Cannabis in the Capital Markets” event
- Patents cover variety of lipophilic bio-actives, including cannabinoids, nicotine and vitamins
- Growing portfolio of intellectual property includes 19 patents filed across 44 countries
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), through its proprietary technology for delivering bioactive compounds in lipid formulations, offers licensed partners the ability to include cannabidiol (CBD) in a variety of ingestible products appropriate for medical patients and recreational users alike. In a new report, Grand View Research, Inc., states that the global market for medical cannabis alone is expected to reach a stunning $55.8 billion by 2025 (http://nnw.fm/Ou2Xa). An increasing interest in the therapeutic value of cannabinoids, especially those delivered in products that can be ingested and not smoked, is one of the main forces driving the market forward, per the report.
Lexaria’s pioneering TurboCBD ™ product presents a revolutionary way to enhance absorption of the benefits CBD provides without having to endure the often unpleasant flavors associated with cannabis compounds. Lexaria’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, with patents pending for THC (tetrahydrocannabinol) and other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and additional molecules.
Dr. Philip Ainsle of the University of British Columbia (UBC) is the principal investigator of Lexaria’s first clinical study of the high-absorption properties of TurboCBD™. The study will evaluate the effects of TurboCBD™ on the cognitive function and cardiovascular health of human volunteers. Dr. Ainsle, co-director of the Centre for Heart, Lung and Vascular Health at the UBC Okanagan Campus in Kelowna, Canada, presented a project update at the Canadian Securities Exchange-sponsored “Cannabis in the Capital Markets” event on September 27 (http://nnw.fm/9MopZ). Lexaria representatives are also scheduled to speak in October at the Southwest Cannabis Conference and Expo in Phoenix, Arizona.
As a business-to-business enterprise, Lexaria’s reach extends to companies located in Canada, several large market states in the U.S., and internationally. An 18-month co-funded research project is underway with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of lipophilic active agents – including those within cannabinoids, vitamins, NSAIDs and nicotine. Results from this study could provide Lexaria with a chemical or physical “fingerprint” that could help to identify Lexaria’s technology at work in consumer products.
Lexaria’s technology is capable of helping companies lower costs while providing the best consumer benefit possible. Several third-party partners have signed deals, letters of intent or memorandums of understanding to utilize Lexaria’s proprietary technology for both THC and CBD products where allowed by law. Lexaria and its partners are targeting markets in Canada, the U.S., Japan, South Korea, Mexico and more. Lexaria’s royalty revenue model includes a range of between five and 10 percent of gross sales.
As a bioscience technology disruptor for edible cannabinoids, Lexaria has several branded CBD products available, including protein energy bars, CBD tablets that contain zero sugar, premium teas and TurboCBD ™ in a high absorption, full spectrum hemp oil capsule. Led by CEO Chris Bunka, Lexaria’s management team includes professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skill sets.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Clinical studies of TurboCBD™ a topic of discussion at Canadian Securities Exchange-sponsored “Cannabis in the Capital Markets” event
- Patents cover variety of lipophilic bio-actives, including cannabinoids, nicotine and vitamins
- Growing portfolio of intellectual property includes 19 patents filed across 44 countries
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), through its proprietary technology for delivering bioactive compounds in lipid formulations, offers licensed partners the ability to include cannabidiol (CBD) in a variety of ingestible products appropriate for medical patients and recreational users alike. In a new report, Grand View Research, Inc., states that the global market for medical cannabis alone is expected to reach a stunning $55.8 billion by 2025 (http://nnw.fm/Ou2Xa). An increasing interest in the therapeutic value of cannabinoids, especially those delivered in products that can be ingested and not smoked, is one of the main forces driving the market forward, per the report.
Lexaria’s pioneering TurboCBD ™ product presents a revolutionary way to enhance absorption of the benefits CBD provides without having to endure the often unpleasant flavors associated with cannabis compounds. Lexaria’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, with patents pending for THC (tetrahydrocannabinol) and other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and additional molecules.
Dr. Philip Ainsle of the University of British Columbia (UBC) is the principal investigator of Lexaria’s first clinical study of the high-absorption properties of TurboCBD™. The study will evaluate the effects of TurboCBD™ on the cognitive function and cardiovascular health of human volunteers. Dr. Ainsle, co-director of the Centre for Heart, Lung and Vascular Health at the UBC Okanagan Campus in Kelowna, Canada, presented a project update at the Canadian Securities Exchange-sponsored “Cannabis in the Capital Markets” event on September 27 (http://nnw.fm/9MopZ). Lexaria representatives are also scheduled to speak in October at the Southwest Cannabis Conference and Expo in Phoenix, Arizona.
As a business-to-business enterprise, Lexaria’s reach extends to companies located in Canada, several large market states in the U.S., and internationally. An 18-month co-funded research project is underway with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of lipophilic active agents – including those within cannabinoids, vitamins, NSAIDs and nicotine. Results from this study could provide Lexaria with a chemical or physical “fingerprint” that could help to identify Lexaria’s technology at work in consumer products.
Lexaria’s technology is capable of helping companies lower costs while providing the best consumer benefit possible. Several third-party partners have signed deals, letters of intent or memorandums of understanding to utilize Lexaria’s proprietary technology for both THC and CBD products where allowed by law. Lexaria and its partners are targeting markets in Canada, the U.S., Japan, South Korea, Mexico and more. Lexaria’s royalty revenue model includes a range of between five and 10 percent of gross sales.
As a bioscience technology disruptor for edible cannabinoids, Lexaria has several branded CBD products available, including protein energy bars, CBD tablets that contain zero sugar, premium teas and TurboCBD ™ in a high absorption, full spectrum hemp oil capsule. Led by CEO Chris Bunka, Lexaria’s management team includes professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skill sets.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼